
Significant Improvement Found in Clinical Trial for Dravet Syndrome
An expert describes the efficacy of fenfluramine in decreasing seizure frequency associated with this rare syndrome.
Fenfluramine proved successful in decreasing seizure frequency in a Phase 3 study of Dravet syndrome, a rare pediatric condition known for its treatment resistance.
In this podcast, Dr. Wilner interviews Arnold Gammaitoni, PharmD, about this potentially game-changing new epilepsy drug.
If these results can be duplicated, it raises the possibility of a new, effective treatment for seizures in children with Dravet syndrome.
RELATED CONTENT:
More podcasts
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.